e-Detail Aid Submission Best Practices

As electronic APSs have become more and more common, we at the PAAB have seen a wide range in how these are submitted.

In order to facilitate the review of electronic APSs, we are providing a guide comprised of best practices for clear and complete submissions. Adoption of these best practices may lead to speedier reviews and fewer resubmissions.

The initial submission for an electronic APS should include:

- an information architecture (IA) showing how the APS is organized and linkages between sections
- a copydeck and user flow
- a layout (if a layout cannot be provided at initial submission, a detailed wireframe for the different pages in the APS)

The following is an example of an information architecture and select copy pages for an iPad detail aid. Please see the sticky notes for feature highlights.




Table of contents



For internal direction only; will not be included in final APS

0.0	Logo page	3
0.0.1	Homepage	4
1.1	Symptoms vs. placebo	5
1.1.1	1 Symptoms vs. DrugABC	
1.1.1.1	Symptom scale	7
1.2	Quality of life	8
1.2.1	QoL scale	9
2.1	Safety overview	10
2.1.1	CNS	12
2.1.2	GI	13
3.1	Drug interactions overview	14
3.1.1	CYP3A4 inhibitors	16
3.1.2	CYP3A4 inducers	17
4.1	Dosing initiation	18
4.2	Dosing considerations	19
4.2.1	Dosing adjustments	20
4.3	Missed doses	21
6.1	Safety information	22
8.1	Study 101 design	24
8.2	Study 102 design	25
9.1	Reference list	26
10.1	Summary page	27

LEGEND: (image) (text) (button) (action)

Footer: visible at all times



(image: home icon)	Tap opens 0.0.1
(image: menu icon)	Tap opens pop-up menu
Safety information	Tap opens 6.1
Product mongraph	Tap directs user to product monograph weblink
Studies	Tap opens 8.1
References	Tap opens 9.1
(image: Drug123 logo)	Tap opens 10.1


Pop-up menu: opens from a tap on all pages

Efficacy	Tap opens 1.1	
•	Sub-menu:	
	Symptoms	Tap opens 1.1
	Qualify of life	Tap opens 1.2
Safety profile	Tap opens 2.1	
Drug interactions	Tap opens 3.1	
Dosing	Tap opens 4.1	
	Sub menu:	
	Initiation	Tap opens 4.1
	Dosing considerations	Tap opens 4.2
	Missed doses	Tap opens 4.3
Summary	Tap opens 10.1	



Section 1.1 Symptoms vs. placebo







	CONTENT	
TEXT & IMAGES	Ctab 1) Symptoms vs. placebo (tab 2) Symptoms vs. DrugABC (chart title) Mean change in symptom score (LOCF) (image) 5 4 3 2 Drug123 DrugABC Week Week Week Week 1 2 3 4	
BUTTONS	(tab 1) Symptoms vs. placebo	Tap opens 1.1 Inactive
	(tab 2) Symptoms vs. DrugABC	mactive
ACTIONS	Swipe left	Opens 1.1.1.1
	Swipe right	Opens 8.2
	Tap on graph	Expands graph to full screen (tap again to close)
NOTES	Footer visible on all pagesSimilar to 1.1	

O 4:	44446
Section	1.1.1.1 Symptom scale (pop-up)
OFCHOLL	I.I.I.I SVIIIDIOIII SCAIE (DOD-UD)

	CONTENT	
TEXT & IMAGES	This scale evaluates:	
BUTTONS	X	Closes this pop-up
NOTES	Footer visible on all pages	